HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development with Highly Advanced Organoid Technology

Featured Story

HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development with Highly Advanced Organoid Technology

HUB Organoids B.V. revolutionizes preclinical and clinical drug development through its cutting-edge organoid technology, enhancing its accuracy and efficiency. San...

Read More

More from HUB

HUB Organoids Launches IntegriGut Screen: A Breakthrough Service Offering for Inflammatory Bowel Disease (IBD) Drug Discovery and Development

HUB Organoids Launches IntegriGut Screen: A Breakthrough Service Offering for Inflammatory Bowel Disease (IBD) Drug Discovery and Development

Utrecht, Netherlands – 25th Jan 2024 – HUB Organoids (HUB), a global leader and sole proprietor of patient-derived organoid technology...

HUB Organoids Announces New Corporate Strategy and Completes Transition from Foundation to Private Company

HUB Organoids Announces New Corporate Strategy and Completes Transition from Foundation to Private Company

[Utrecht, July 18 2023] — HUB Organoids (HUB), the global leader in the field of patient-derived organoids, is excited to...

FDA Modernization Act 2.0: We welcome the dawn of an organoid era

FDA Modernization Act 2.0: We welcome the dawn of an organoid era

X

Have any questions?

contact us